» Articles » PMID: 21641676

Reappraisal of the Provisional Entity Primary Cutaneous CD4+ Small/medium Pleomorphic T-cell Lymphoma: a Series of 10 Adult and Pediatric Patients and Review of the Literature

Overview
Specialty Dermatology
Date 2011 Jun 7
PMID 21641676
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Primary cutaneous CD4(+) small/medium-sized pleomorphic T-cell lymphoma (PCSM-TCL) was defined as a provisional entity in the 2005 World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas. A limited number of reports describe a generally indolent but heterogeneous condition.

Objective: We reviewed the concept of PCSM-TCL when applied to our experience and to the published literature.

Methods: We conducted a retrospective chart review and a PubMed search to identify all reported cases of PCSM-TCL from 2005 to 2010.

Results: Ten patients, including 4 of the youngest described, were identified in our institution, and their clinical and pathologic features were analyzed. All had a benign clinical course. Ten reports of patients with PCSM-TCL were reviewed and commonalities were found within an otherwise variable spectrum of clinical presentation, pathology, and biologic behavior.

Limitations: This study was retrospective, follow-up was short term in some cases, and data were limited in a number of published reports.

Conclusions: Our experience of 10 cases that met the diagnostic criteria of the provisional entity PCSM-TCL highlights its occurrence in children and further supports characterization of this condition as a clonal T-cell lymphoproliferative disorder with indolent behavior.

Citing Articles

Paediatric cutaneous lymphomas including rare subtypes: A 40-year experience at a tertiary referral centre.

Alberti-Violetti S, Avallone G, Colonna C, Tavoletti G, Venegoni L, Merlo V J Eur Acad Dermatol Venereol. 2024; 39(1):161-170.

PMID: 38650545 PMC: 11664474. DOI: 10.1111/jdv.20028.


Recent advances in cutaneous lymphoma-implications for current and future classifications.

Goodlad J, Cerroni L, Swerdlow S Virchows Arch. 2022; 482(1):281-298.

PMID: 36278991 PMC: 9852132. DOI: 10.1007/s00428-022-03421-5.


Primary cutaneous CD4+ small/medium T-cell lymphoma: a case report.

Kim J, Jeong M, Jun D, Lee M, Shin D, Kim W Arch Craniofac Surg. 2021; 22(4):199-203.

PMID: 34474543 PMC: 8413923. DOI: 10.7181/acfs.2021.00199.


Case for diagnosis. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.

Valentim F, Oliveira C, Miot H An Bras Dermatol. 2019; 94(1):99-101.

PMID: 30726474 PMC: 6360982. DOI: 10.1590/abd1806-4841.20198513.


New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Fujii K Front Oncol. 2018; 8:198.

PMID: 29915722 PMC: 5994426. DOI: 10.3389/fonc.2018.00198.